Skip to content
DraconiticResearch
Search Sources API
197,693 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BY-NCHuman vaccines & immunotherapeutics

RSV vaccine uptake among Medicare Advantage enrollees: August 2023 to December 2024.

  • Vishal Saundankar1
  • Reiko Sato2
  • Robyn Moucka2
  • Pamela Smith2
  • Kimbal Ford2
  • Edward W Casey2
  • Chris Barger3
  • Richard Sheer1
  • Brandon Suehs1
  1. 1Humana Healthcare Research, Inc., Louisville, KY, USA.
  2. 2Pfizer, Inc., Collegeville, PA, USA.
  3. 3Humana, Inc., Louisville, KY, USA.
Read full textPDFDOICite

Abstract

Respiratory syncytial virus (RSV) is one of the most common causes of respiratory tract infections, disproportionately affecting young children, older adults, and those with chronic medical conditions. In the US, RSV vaccine recommendations by the US Centers for Disease Control (CDC) for adults were first issued in 2023 and have since evolved. Uptake of the RSV vaccine by eligible US adults has been slower than expected, with approximately one-fifth (21.0%) of adults aged ≥ 65 years enrolled in Medicare fee-for-service plans receiving the vaccine in the first season of availability. We analyzed RSV vaccine uptake over two seasons among older adults enrolled in Medicare Advantage. Overall RSV vaccine uptake was higher in the 2023/2024 season compared with the 2024/2025 season, peaking in October of both years. Adults ≥ 75 years had higher vaccine uptake than those 65-74 years. Vaccination was highest among groups at increased risk for severe RSV illness. Among approximately 1.7 MM individuals who met the 2024 CDC recommendations for vaccination, roughly 80% did not have evidence of RSV vaccination. Targeted strategies are needed to further reach adults who are at increased risk for severe RSV illness.

Related

  1. Performance of Chronic Conditions Data Warehouse algorithms in Medicare Advantage and fee-for-service populations
    Chan Mi Park, Xiecheng Chen, Sandra Shi +6
    The Journals of Gerontology Series A: Biological Sciences and Medical SciencesPeer-reviewedPublisher termsFull textGeneral medicinePMC
  2. Performance of Claims-based Alzheimer’s Disease and Related Dementias Algorithms in Medicare Advantage and Fee-for-Service Populations
    You Wu, Chan Mi Park, Xiecheng Chen +5
    The journals of gerontology. Series A, Biological sciences and medical sciencesPeer-reviewedLicence not statedFull textPsychiatry & mental healthPMC
  3. Characteristics and Financial Implications of Measures Removed From Medicare Advantage Star Ratings
    Derek T. Lake, Yasin Civelek, Amelia M. Bond +1
    JAMA Network OpenPeer-reviewedCC BY-NC-NDFull textGeneral medicineCrossrefEurope PMC
  4. Trends in detection of dementia among beneficiaries in Medicare advantage and traditional Medicare.
    Yuting Qian, Heather Allore, Xi Chen
    Alzheimer's & dementia (Amsterdam, Netherlands)Peer-reviewedCC BY-NC-NDFull textPsychiatry & mental healthEurope PMC
  5. Rural/Urban Disparities in Pneumococcal Vaccine Service Delivery Among the Fee-for-Service Medicare Population
    Jeffery Talbert, Aric D. Schadler, Patricia Rippetoe Freeman
    UKnowledge (University of Kentucky)Peer-reviewedLicence not statedFull text9 citedEpidemiology & public healthOpenAlex

Cite

BibTeXRIS
BibTeX
@article{saundankar2026vaccine,
  title = {{RSV vaccine uptake among Medicare Advantage enrollees: August 2023 to December 2024.}},
  author = {Vishal Saundankar and Reiko Sato and Robyn Moucka and Pamela Smith and Kimbal Ford and Edward W Casey and Chris Barger and Richard Sheer and Brandon Suehs},
  journal = {Human vaccines \& immunotherapeutics},
  year = {2026},
  month = oct,
  doi = {10.1080/21645515.2026.2745402},
  url = {https://europepmc.org/article/MED/42872881},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - RSV vaccine uptake among Medicare Advantage enrollees: August 2023 to December 2024.
AU  - Vishal Saundankar
AU  - Reiko Sato
AU  - Robyn Moucka
AU  - Pamela Smith
AU  - Kimbal Ford
AU  - Edward W Casey
AU  - Chris Barger
AU  - Richard Sheer
AU  - Brandon Suehs
PY  - 2026
DA  - 2026/10/14
JO  - Human vaccines & immunotherapeutics
DO  - 10.1080/21645515.2026.2745402
UR  - https://europepmc.org/article/MED/42872881
AB  - Respiratory syncytial virus (RSV) is one of the most common causes of respiratory tract infections, disproportionately affecting young children, older adults, and those with chronic medical conditions. In the US, RSV vaccine recommendations by the US Centers for Disease Control (CDC) for adults were first issued in 2023 and have since evolved. Uptake of the RSV vaccine by eligible US adults has been slower than expected, with approximately one-fifth (21.0%) of adults aged ≥ 65 years enrolled in Medicare fee-for-service plans receiving the vaccine in the first season of availability. We analyzed RSV vaccine uptake over two seasons among older adults enrolled in Medicare Advantage. Overall RSV vaccine uptake was higher in the 2023/2024 season compared with the 2024/2025 season, peaking in October of both years. Adults ≥ 75 years had higher vaccine uptake than those 65-74 years. Vaccination was highest among groups at increased risk for severe RSV illness. Among approximately 1.7 MM individuals who met the 2024 CDC recommendations for vaccination, roughly 80% did not have evidence of RSV vaccination. Targeted strategies are needed to further reach adults who are at increased risk for severe RSV illness.
SN  - 2164-5515
SN  - 2164-554X
ER  -